Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keisuke Kidoguchi

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Internal Medicine (Tokyo, Japan)|August 6, 2025
Low Generic Drug Penetration for Expensive Oral Molecular Targeted Agents: An Experience with Generic Imatinib in JapanKeisuke Kidoguchi, Hiroshi Ureshino, Shinya Kimura
Cancer Science|January 21, 2025
Treating Hematological Malignancies With OR-2100, an Orally Bioavailable Prodrug of DecitabineTatsuro Watanabe, Keisuke Kidoguchi, Shinya Kimura
Ejhaem|December 18, 2024
IFN-α treatment may enable discontinuation of TKIs in NK cell-licensed patients with CML-CPHiroshi Ureshino, Kazuharu Kamachi, Keisuke Kidoguchi, et al.
Cancer Medicine|August 11, 2025
Clinical Features and T-Cell Repertoire of Chronic Myeloid Leukemia Patients Who Attempt Discontinuation of Tyrosine Kinase Inhibitors: The ISAC-TFR StudyHiroshi Ureshino, Yukio Nakamura, Yemima Budirahardja, et al.
International Journal of Molecular Sciences|October 26, 2024
Targeting Oxidative Phosphorylation with a Novel Thiophene Carboxamide Increases the Efficacy of Imatinib against Leukemic Stem Cells in Chronic Myeloid LeukemiaKana Kusaba, Tatsuro Watanabe, Keisuke Kidoguchi, et al.
International Journal of Hematology|April 28, 2021
Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single instituteKeisuke Kidoguchi, Hiroshi Ureshino, Haruna Kizuka-Sano, et al.
Cancers|October 28, 2023
A Combination of Alectinib and DNA-Demethylating Agents Synergistically Inhibits Anaplastic-Lymphoma-Kinase-Positive Anaplastic Large-Cell Lymphoma Cell ProliferationKazunori Kawasoe, Tatsuro Watanabe, Nao Yoshida-Sakai, et al.
International Journal of Hematology|March 19, 2020
Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donorToshihiko Ando, Haruna Sano, Masako Yokoo, et al.
Internal Medicine (Tokyo, Japan)|May 17, 2021
Aplastic Anemia in a Patient with Cronkhite-Canada SyndromeKeisuke Kidoguchi, Yasushi Kubota, Shun Fujimoto, et al.
Internal Medicine (Tokyo, Japan)|September 18, 2024
Pure Red Cell Aplasia in a Patient with Thymic Hyperplasia, Hypogammaglobulinemia and Adult T-cell Leukemia/LymphomaYasushi Kubota, Haruhiko Sano, Yuji Takeda, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Internal Medicine (Tokyo, Japan)|August 6, 2025
Low Generic Drug Penetration for Expensive Oral Molecular Targeted Agents: An Experience with Generic Imatinib in JapanKeisuke Kidoguchi, Hiroshi Ureshino, Shinya Kimura
Cancer Science|January 21, 2025
Treating Hematological Malignancies With OR-2100, an Orally Bioavailable Prodrug of DecitabineTatsuro Watanabe, Keisuke Kidoguchi, Shinya Kimura
Ejhaem|December 18, 2024
IFN-α treatment may enable discontinuation of TKIs in NK cell-licensed patients with CML-CPHiroshi Ureshino, Kazuharu Kamachi, Keisuke Kidoguchi, et al.
Cancer Medicine|August 11, 2025
Clinical Features and T-Cell Repertoire of Chronic Myeloid Leukemia Patients Who Attempt Discontinuation of Tyrosine Kinase Inhibitors: The ISAC-TFR StudyHiroshi Ureshino, Yukio Nakamura, Yemima Budirahardja, et al.
International Journal of Molecular Sciences|October 26, 2024
Targeting Oxidative Phosphorylation with a Novel Thiophene Carboxamide Increases the Efficacy of Imatinib against Leukemic Stem Cells in Chronic Myeloid LeukemiaKana Kusaba, Tatsuro Watanabe, Keisuke Kidoguchi, et al.
International Journal of Hematology|April 28, 2021
Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single instituteKeisuke Kidoguchi, Hiroshi Ureshino, Haruna Kizuka-Sano, et al.
Cancers|October 28, 2023
A Combination of Alectinib and DNA-Demethylating Agents Synergistically Inhibits Anaplastic-Lymphoma-Kinase-Positive Anaplastic Large-Cell Lymphoma Cell ProliferationKazunori Kawasoe, Tatsuro Watanabe, Nao Yoshida-Sakai, et al.
International Journal of Hematology|March 19, 2020
Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donorToshihiko Ando, Haruna Sano, Masako Yokoo, et al.
Internal Medicine (Tokyo, Japan)|May 17, 2021
Aplastic Anemia in a Patient with Cronkhite-Canada SyndromeKeisuke Kidoguchi, Yasushi Kubota, Shun Fujimoto, et al.
Internal Medicine (Tokyo, Japan)|September 18, 2024
Pure Red Cell Aplasia in a Patient with Thymic Hyperplasia, Hypogammaglobulinemia and Adult T-cell Leukemia/LymphomaYasushi Kubota, Haruhiko Sano, Yuji Takeda, et al.
Pageof 3